Plasma components: FFP, FP24, and Thawed Plasma

Immunohematology

Volumn 23, Issue 4, 2007, Pages 150-157

  Eder, Anne F ^a   Sebok, Melissa A ^a  

^a AMERICAN RED CROSS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; FRESH FROZEN PLASMA;

ANTIBODY LABELING; ENZYME ACTIVITY; PHLEBOTOMY; PLASMA TRANSFUSION; PRIORITY JOURNAL; REVIEW; THAWING; TREATMENT INDICATION;

BLOOD COAGULATION; BLOOD COMPONENT TRANSFUSION; BLOOD PRESERVATION; BLOOD PROTEINS; FREEZING; HUMANS; PLASMA; SPECIMEN HANDLING; TEMPERATURE; TIME FACTORS;

EID: 38549122334     PISSN: 0894203X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Plasma Components. Circular of Information for the Use of Human Blood and Blood Components, AABB; America's Blood Centers, American Red Cross, 2002.
2. Standard 5.7.5.12. Standards for Blood Banks and Transfusion Services. 24th ed. Bethesda: AABB, 2006:30.
3. Code of Federal Regulations, 21 CFR 640.34(a) and (b).
4. United Kingdom Blood Transfusion Services/National Institute for Biological Standards and Control, 2002.
5. British Committee for Standards in Haematology. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br Soc Haematol 2004;126:11-28.
6. Vassallo R. Issues to consider when converting frozen plasma into thawed plasma. AABB News 2007;9:16-7.
7. Casper KK, Brooker M. Registry of Clotting Factor Concentrates, International Society on Thrombosis and Hemostasis, http://www.med.unc.edu/isth/ databases/clotting_factors/2006_registry_clotting_factor_concentrates.pdf.
8. Miller CH, Haff E, Platt SJ, et al. Measurement of von Willebrand factor activity: relative effects of ABO blood type and race. J Thromb Haemost 2003;1:2191-7.
9. Andrew M, Vegh P, Johnston, et al. Maturation of the hemostatic system during childhood. Blood 1992;80:1998-2005.
10. Andrew M, Paes B, Milner R, et al. Development of the human coagulation system in the healthy premature infant. Blood 1988; 72:1651-7.
11. Smith JF, Ness PM, Moroff G, Luban NLC. Retention of coagulation factors in plasma frozen after extended holding at 1-6°C. Vox Sang 2000;78:28-30.
12. O'Neill EM, Royley J, Hansson-Wicher M, et al. Effect of 24-hour whole-blood storage on plasma clotting factors. Transfusion 1999;39:488-91.
13. Cardigan R, Lawrie AS, Mackie IJ, Williamson LM. The quality of fresh-frozen plasma produced form whole blood stored at 4°C overnight. Transfusion 2005;45:1342-8.
14. Downes KA, Wilson E, Yomtovian R, Sarode R. Serial measurement of clotting factors in thawed plasma stored for 5 days. (Letter) Transfusion 2001;41:570.
15. Sidhu RS, Le T, Brimhall B, Thompson H. Study of coagulation factor activities in apheresed thawed fresh frozen plasma at 1-6°C for five days. J Clin Apher 2006;21:224-6.
16. Scott EA, Puca KE, Pietz BC, et al. Comparison and stability of ADAMTS13 activity in therapeutic plasma products.Transfusion 2007;47:1205.
17. Runkel S, Haubelt H, Hitzler W, Hellstern P. The quality of plasma collected by automated apheresis and of recovered plasma from leukodepleted whole blood. Transfusion 2005;45:427-32.
18. Nifong TP, Light J, Wenk RE. Coagulant stability and sterility of thawed S/D-treated plasma. Transfusion 2002;42:1581-4.
19. Hellstern P, Haubelt H. Manufacture and composition of fresh frozen plasma and virus inactivated therapeutic plasma: correlation between composition and therapeutic efficacy. Thromb Res 2002;107(Suppl):S3-8.
20. Williamson LM, Llewelyn CA, Fisher NC, et al. A randomised trial of solvent/detergent and standard fresh frozen plasma in the coagulopathy of liver disease and liver transplantation.Transfusion 1999;39:1227-34.
21. Haubelt H, Blome M, Kiessling AH, et al. Effects of solvent/detergent- treated plasma and fresh-frozen plasma on haemostasis and fibrinolysis in complex coagulopathy following open-heart surgery. Vox Sang 2002;82:9-14.
22. Horowitz MS, Pehta JC. SD plasma in TTP and coagulation factor deficiencies for which no concentrates are available. Vox Sang 1998;74(Suppl 1):231-5.
23. Alford BL. Important new drug warning (letter). Watertown, MA: Vitex Technologies, March 29, 2002.
24. de Jonge J, Groenland THN, Metselaar HJ, et al. Fibrinolysis during liver transplantation is enhanced by using solvent/detergent virus-inactivated plasma (ESDEP). Anesth Analg 2002;94:1127-31.
25. Magner JJ, Crowley KJ, Boylan JF. Fatal fibrinolysis during orthotopic liver transplantation in patients receiving solvent/detergent-treated plasma (Octaplas). J Cardiothorac Vasc Anesth 2007;21:410-3.
26. Bostrom F, Sjodahl M, Wehlin L, et al. Coagulation parameters in apheresis and leukodepleted whole-blood plasma during storage. Transfusion 2007;47:460-3.
27. Palo R, Capraro L, Hovilehto S, et al. Population-based audit of fresh-frozen plasma transfusion practices. Transfusion 2006;46:1921-5.
28. Wallis JP, Dzik WH. Is fresh frozen plasma overtransfused in the United States? (editorial). Transfusion 2004;44:1674-5.
29. Dzik W, Rao A. Why do physicians request fresh frozen plasma? (Letter) Transfusion 2004;44:1393.
30. Abdel-Wahab OI, Healy B, Dzik WH. Effect of fresh-frozen plasma transfusion on prothrombin time and bleeding in patients with mild coagulation abnormalities. Transfusion 2006;46:1279-85.
31. Stanworth SJ, Brunskill SJ, Hyde CJ, et al. Is fresh frozen plasma clinically effective? A systematic review of randomized controlled trials. Br J Haematol 2004;126:139-52.
32. Strong DM, Lipton KS. Transfusion-related acute lung injury. AABB Association Bulletin #06-07, November 3, 2006. Bethesda: AABB.
33. Triulzi DJ. The art of plasma transfusion therapy. Transfusion 2006;46:1268-70.